Aktienanalyse zu Theravance Biopharma Inc (TBPH)TBPHTheravance Biopharma Inc

Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development and commercialization of medicines for the specialty respiratory and neurologic diseases. The Company operates through a single segment, namely, development and commercialization of human therapeutics. Its product, YUPELRI (revefenacin) inhalation solution, is a nebulized long-acting muscarinic antagonist used for the treatment of patients with chronic obstructive pulmonary disease (COPD). COPD is a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in the lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Its Ampreloxetine, is a late-stage investigational norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension in patients with Multiple System Atrophy. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Theravance Biopharma is currently a hold due to its acquisition by Zymeworks at $17 per share, which reflects a 22% premium, but the stock has shown mixed performance with a recent RSI of 76.26 indicating overbought conditions. The downgrade from analysts and a YTD change of -6.06% suggest caution, despite the potential for future earnings from the acquisition.

7 analysts cover TBPH: 4 rate it Buy, 0 Hold and 3 Sell. The average price target is 28.40.